Literature DB >> 15964405

Intraosseus transplantation of donor-derived hematopoietic stem and progenitor cells induces donor-specific chimerism and extends composite tissue allograft survival.

M Siemionow1, M Zielinski, S Ozmen, D Izycki.   

Abstract

We investigated the effect of the intraosseous allotransplantation of the donor-derived hematopoietic stem cells (HSC) CD90+ on chimerism induction and survival of rat hind limb transplants. Eighteen rat hind limb transplantations were performed between Lewis-Brown-Norway and Lewis rats in three groups. Isograft and allograft rejection controls received no treatment. In the experimental group, 0.8 to 1.2 x 10(6) of separated and purified CD90+ HSC cells were transplanted intramedullary into the bone marrow cavity of the recipient's tibia during opposite hind limb transplantation, without immunosuppressive therapy. Transplants from isograft group survived indefinitely. Allograft controls rejected transplants on day 7 posttransplant. The injection of separated and purified CD90+ cells of the donor origin extended survival of the transplanted limbs up to 15 days in group III. We introduced a novel method of transplantation of the CD90+ cells of the donor origin into the recipient's bone marrow cavity. This technique resulted in extended allograft survival, without immunosuppressive therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15964405     DOI: 10.1016/j.transproceed.2005.03.127

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  10 in total

1.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

Review 2.  Current landscape for T-cell targeting in autoimmunity and transplantation.

Authors:  Daniel R Getts; Sushma Shankar; Emily M L Chastain; Aaron Martin; Meghann Teague Getts; Kathryn Wood; Stephen D Miller
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

3.  Mesenchymal stem cells systemically injected into femoral marrow of dogs home to mandibular defects to enhance new bone formation.

Authors:  Xian Liu; Xuejuan Liao; En Luo; Wenchuan Chen; Chongyun Bao; Hockin H K Xu
Journal:  Tissue Eng Part A       Date:  2014-01-20       Impact factor: 3.845

4.  Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Sonia Brodowska; Katarzyna Kozlowska; Kristina Zalants; Katarzyna Budzynska; Ahlke Heydemann
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 6.692

5.  Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts.

Authors:  Joanna Cwykiel; Arkadiusz Jundzill; Aleksandra Klimczak; Maria Madajka-Niemeyer; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-10       Impact factor: 4.291

6.  Translating tolerogenic therapies to the clinic - where do we stand?

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

7.  Intra-Bone Marrow Transplantation of Endosteal Bone Marrow Cells Facilitates Allogeneic Hematopoietic and Stromal Cells Engraftment Dependent on Early Expression of CXCL-12.

Authors:  Chen Chen; Yingjun Su; Jianwu Chen; Dongliang Zhang; Yajuan Song; Shuzhong Guo
Journal:  Med Sci Monit       Date:  2015-09-16

8.  Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; M Malik; P Langa; J Cwykiel; S Brodowska; A Heydemann
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

9.  Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience.

Authors:  Maria Siemionow; Aleksandra Klimczak
Journal:  Clin Dev Immunol       Date:  2013-03-14

10.  Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Michal Harasymczuk; Joanna Cwykiel; Magdalena Sielewicz; Jaroslaw Smieszek; Ahlke Heydemann
Journal:  Stem Cells Transl Med       Date:  2021-07-22       Impact factor: 6.940

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.